ENGN enGene Therapeutics Inc.
$1.80▲ +1.69%
Healthcare
Other
After hours
$1.80▲ +0.00%
Sep 11, 7:30 PM ET
Volume 651.0K
Avg Volume (10D) 631.7K
Key Metrics & Fundamentals
Market Cap
$120.63M
P/E Ratio
–
Div Yield
–%
52W Range
1.40 - 12.25
% vs 50 MA
-3.01%
% vs 200 MA
-68.19%
RSI-14
45.2
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.16
Free Cash Flow
-$18.95M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$31.48M
COGS
–
Operating Exp
$34.01M
Operating Income
-$34.01M
EBIT
-$34.01M
Pretax Income
-$32.50M
Net Income
-$32.50M
EPS (Diluted)
-0.47
Price & Volume History
Loading chart…
Recent News
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire · Sep 8, 2026 11:30 AM
enGene to Participate in Upcoming Investor Conferences
Business Wire · Sep 1, 2026 12:30 PM
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
MarketBeat · Aug 13, 2026 3:07 PM
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
Business Wire · Aug 4, 2026 12:00 PM
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
GlobeNewswire · Jul 15, 2026 1:00 PM
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · Jun 18, 2026 7:32 PM
Neumora depression drug fails; EnGene to cut 50% of staff
BioPharma Dive · Jun 16, 2026 9:08 AM
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Jun 15, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ENGN's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.